Literature DB >> 33419255

Biological Characteristics and Osteogenic Differentiation of Ovine Bone Marrow Derived Mesenchymal Stem Cells Stimulated with FGF-2 and BMP-2.

Sandra Gromolak1, Agnieszka Krawczenko1, Agnieszka Antończyk2, Krzysztof Buczak2, Zdzisław Kiełbowicz2, Aleksandra Klimczak1.   

Abstract

Cell-based therapies using mesenchymal stem cells (MSCs) are a promising tool in bone tissue engineering. Bone regeneration with MSCs involves a series of molecular processes leading to the activation of the osteoinductive cascade supported by bioactive factors, including fibroblast growth factor-2 (FGF-2) and bone morphogenetic protein-2 (BMP-2). In this study, we examined the biological characteristics and osteogenic differentiation potential of sheep bone marrow MSCs (BM-MSCs) treated with 20 ng/mL of FGF-2 and 100 ng/mL BMP-2 in vitro. The biological properties of osteogenic-induced BM-MSCs were investigated by assessing their morphology, proliferation, phenotype, and cytokine secretory profile. The osteogenic differentiation was characterized by Alizarin Red S staining, immunofluorescent staining of osteocalcin and collagen type I, and expression levels of genetic markers of osteogenesis. The results demonstrated that BM-MSCs treated with FGF-2 and BMP-2 maintained their primary MSC properties and improved their osteogenic differentiation capacity, as confirmed by increased expression of osteocalcin and collagen type I and upregulation of osteogenic-related gene markers BMP-2, Runx2, osterix, collagen type I, osteocalcin, and osteopontin. Furthermore, sheep BM-MSCs produced a variety of bioactive factors involved in osteogenesis, and supplementation of the culture medium with FGF-2 and BMP-2 affected the secretome profile of the cells. The results suggest that sheep osteogenic-induced BM-MSCs may be used as a cellular therapy to study bone repair in the preclinical large animal model.

Entities:  

Keywords:  bone marrow MSCs; bone repair; large animal model; osteogenic differentiation

Mesh:

Substances:

Year:  2020        PMID: 33419255      PMCID: PMC7766718          DOI: 10.3390/ijms21249726

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  56 in total

Review 1.  Growth regulatory factors and bone.

Authors:  G R Mundy; D Chen; M Zhao; S Dallas; C Xu; S Harris
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

3.  Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy.

Authors:  Hiroshi Kawaguchi; Seiya Jingushi; Toshihiro Izumi; Masao Fukunaga; Takashi Matsushita; Takashi Nakamura; Kosaku Mizuno; Toshitaka Nakamura; Kozo Nakamura
Journal:  J Orthop Res       Date:  2007-04       Impact factor: 3.494

4.  Optimization of release pattern of FGF-2 and BMP-2 for osteogenic differentiation of low-population density hMSCs.

Authors:  Lei Lei; Shuo Wang; Honghui Wu; Wei Ju; Jian Peng; Anwar Saeed Ahmed Qahtan; Chen Chen; Yanqin Lu; Jieying Peng; Xing Zhang; Hemin Nie
Journal:  J Biomed Mater Res A       Date:  2014-04-02       Impact factor: 4.396

5.  Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity.

Authors:  Y Takeuchi; Y Kodama; T Matsumoto
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

6.  FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.

Authors:  Filippos Kottakis; Christos Polytarchou; Parthena Foltopoulou; Ioannis Sanidas; Sotirios C Kampranis; Philip N Tsichlis
Journal:  Mol Cell       Date:  2011-07-22       Impact factor: 17.970

Review 7.  Local drug delivery for enhancing fracture healing in osteoporotic bone.

Authors:  Laura Kyllönen; Matteo D'Este; Mauro Alini; David Eglin
Journal:  Acta Biomater       Date:  2014-09-16       Impact factor: 8.947

8.  Osteocalcin Mediates Biomineralization during Osteogenic Maturation in Human Mesenchymal Stromal Cells.

Authors:  Yu-Tzu Tsao; Yi-Jeng Huang; Hao-Hsiang Wu; Yu-An Liu; Yi-Shiuan Liu; Oscar K Lee
Journal:  Int J Mol Sci       Date:  2017-01-17       Impact factor: 5.923

Review 9.  Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease.

Authors:  J Douglas Coffin; Collin Homer-Bouthiette; Marja Marie Hurley
Journal:  J Endocr Soc       Date:  2018-05-28

10.  Can supernatant from immortalized adipose tissue MSC replace cell therapy? An in vitro study in chronic wounds model.

Authors:  Honorata Kraskiewicz; Maria Paprocka; Aleksandra Bielawska-Pohl; Agnieszka Krawczenko; Kinga Panek; Judyta Kaczyńska; Agnieszka Szyposzyńska; Mateusz Psurski; Piotr Kuropka; Aleksandra Klimczak
Journal:  Stem Cell Res Ther       Date:  2020-01-21       Impact factor: 6.832

View more
  3 in total

1.  Co-transfection with BMP2 and FGF2 via chitosan nanoparticles potentiates osteogenesis in human adipose-derived stromal cells in vitro.

Authors:  Ying Hu; Qing-Wei Zhao; Zheng-Cai Wang; Qing-Qing Fang; He Zhu; Dong-Sheng Hong; Xing-Guang Liang; Dong Lou; Wei-Qiang Tan
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 2.  Mesenchymal Stem Cells, Bioactive Factors, and Scaffolds in Bone Repair: From Research Perspectives to Clinical Practice.

Authors:  Sandra Stamnitz; Aleksandra Klimczak
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

Review 3.  Application of BMP in Bone Tissue Engineering.

Authors:  Liwei Zhu; Yuzhe Liu; Ao Wang; Zhengqing Zhu; Youbin Li; Chenyi Zhu; Zhenjia Che; Tengyue Liu; He Liu; Lanfeng Huang
Journal:  Front Bioeng Biotechnol       Date:  2022-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.